The goals of the proposed research are to determine the mechanisms that lead to the development of necrotizing enterocolitis (NEC), which is the leading cause of death and disability from gastrointestinal disease in premature infants, and to determine novel therapeutic strategies for this devastating disorder. To accomplish these goals, we now focus on the innate immune receptor Toll like receptor-4 (TLR4), which is known to be the receptor for lipopolysaccharide (LPS), and which in the first funding period, we have identified to play a critical role in the pathogenesis of this disease. We now seek to define the molecular and cellular mechanisms by which TLR4 activation leads to NEC. To do so, we generated mice that lack TLR4 specifically on the intestinal epithelium, which were found to be protected from NEC development as compared with wild-type mice. In seeking to understand the mechanisms involved, we now demonstrate that TLR4 exerts an important and previously unrecognized role in the regulation of normal intestinal epithelial differentiation. We also determined that TLR4 is expressed on the intestinal stem cells (ISC's), and that ISC proliferation - a key determinant of the ability of the intestinal mucosa to heal - is reduced in NEC. To define whether TLR4 activation on ISC's was required for the loss of ISC proliferation, we generated mice that lack TLR4 specifically on the ISC's, which showed intact proliferation after TLR4 activation compared with wild-type mice. We now hypothesize that inappropriate TLR4 signaling in the preterm infant leads to the development of NEC by impairing the activity and function of the intestinal stem cells. To test this hypothesize we propose the following three aims:
Aim 1. To investigate the role of TLR4 activation in regulating intestinal epithelial differentiation in the pathogenesis of necrotizing enterocolitis.
Aim 2. To determine the effects of inappropriate activation of TLR4 in the developing intestine on the induction of intestinal inflammation.
Aim 3. To characterize the role of TLR4-mediated loss of intestinal stem cell proliferation in the pathogenesis of necrotizing enterocolitis, and to determine whether restoring intestinal stem cell proliferation can prevent or attenuate the severity of the disease. To accomplish these research goals, we have generated mice strains that lack or overexpress TLR4 in intestinal epithelium or that lack TLR4 on the ISC's, have developed techniques of intestinal stem cell isolation and culture and have successfully introduced TLR4 agonists into the developing mouse intestine in utero. These studies will make a significant conceptual advance in linking the innate immune system with intestinal development, will advance our understanding of NEC by explaining the susceptibility of the premature infant based on the role of TLR4 in the intestinal stem cells, and will evaluate novel anti-NEC therapies which seek to reverse the deleterious effects of TLR4 on the ability of the intestinal stem cells to repair the injured mucosa of the premature small intestine.

Public Health Relevance

Necrotizing enterocolitis is the leading cause of death from gastrointestinal disease in premature infants, and for which there exists no effective cure. The current proposal seeks to understand the causes of necrotizing enterocolitis by focusing on the interaction between the immune system and the stem cells of the newborn intestine, and therefore to discover novel treatments for this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM078238-08
Application #
8585075
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Somers, Scott D
Project Start
2006-09-01
Project End
2015-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
8
Fiscal Year
2014
Total Cost
$262,267
Indirect Cost
$86,767
Name
University of Pittsburgh
Department
Surgery
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Cunningham, Kellie E; Vincent, Garret; Sodhi, Chhinder P et al. (2016) Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis. J Biol Chem 291:10184-200
Jia, Hongpeng; Sodhi, Chhinder P; Yamaguchi, Yukihiro et al. (2016) Pulmonary Epithelial TLR4 Activation Leads to Lung Injury in Neonatal Necrotizing Enterocolitis. J Immunol 197:859-71
Egan, Charlotte E; Sodhi, Chhinder P; Good, Misty et al. (2016) Toll-like receptor 4-mediated lymphocyte influx induces neonatal necrotizing enterocolitis. J Clin Invest 126:495-508
Deng, Meihong; Ma, Tao; Yan, Zhengzheng et al. (2016) Toll-like Receptor 4 Signaling on Dendritic Cells Suppresses Polymorphonuclear Leukocyte CXCR2 Expression and Trafficking via Interleukin 10 During Intra-abdominal Sepsis. J Infect Dis 213:1280-8
Fritz, Michael; Klawonn, Anna M; Nilsson, Anna et al. (2016) Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice. J Clin Invest 126:695-705
Ladd, Mitchell R; Niño, Diego F; March, John C et al. (2016) Generation of an artificial intestine for the management of short bowel syndrome. Curr Opin Organ Transplant 21:178-85
Niño, Diego F; Sodhi, Chhinder P; Hackam, David J (2016) Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat Rev Gastroenterol Hepatol 13:590-600
Shaffiey, Shahab A; Jia, Hongpeng; Keane, Timothy et al. (2016) Intestinal stem cell growth and differentiation on a tubular scaffold with evaluation in small and large animals. Regen Med 11:45-61
Good, Misty; Sodhi, Chhinder P; Yamaguchi, Yukihiro et al. (2016) The human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine. Br J Nutr 116:1175-1187
Arnaoutakis, Dean J; Kim, Yuhree; Pulitano, Carlo et al. (2015) Management of biliary cystic tumors: a multi-institutional analysis of a rare liver tumor. Ann Surg 261:361-7

Showing the most recent 10 out of 63 publications